Nascent clinical biotech Septerna added to the slight uptick in IPO fervor this fall with its $288 million Nasdaq listing on Friday.
Investors seemed enthused …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Jeremy Faust is editor-in-chief of MedPage Today, an emergency medicine physician at Brigham and Women’s Hospital in Boston, and a public health researcher. He is
Today, Cybin Inc. (NASDAQ: CYBN) (CBOE :CYBN) unveiled its much-anticipated Phase 2 interim findings for CYB003, a proprietary deuterated psilocybin analog. The results showcase a
Insilico Medicine (“Insilico”), a generative artificial intelligence (AI)-driven clinical-stage drug discovery company, today announced the nomination of ISM8001, a novel molecule targeting FGFR2/3 for the